Andreas Torp Kristensen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Andreas Torp Kristensen has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Buddheera Bandara Wm Kumburegama
Copenhagen Trial Unit, Centre for Clinical Intervention Research; The Capital Region, Copenhagen University Hospital — Rigshospitalet; Copenhagen Denmark
2 shared publications - Christian Gluud
Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region, Department 7812, Copenhagen University Hospital ─ Rigshospitalet, Copenhagen, Denmark
2 shared publications - Dimitrinka Nikolova
Cochrane Hepato‑Biliary Group, Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region, Copenhagen University Hospital ─ Rigshospitalet, Copenhagen, Denmark
2 shared publications - Goran Bjelakovic
Department of Internal Medicine, Medical Faculty, University of Nis, Nis, Serbia
2 shared publications Janus C Jakobsen
Copenhagen Trial Unit, Rigshospitalet, Kobenhavn, Denmark
2 shared publications- Milica Bjelakovic
Medical Faculty, University of Niš, Niš, Serbia
2 shared publications
Latest Publications
- Open Access
- 31 January 2026
- Published by Springer Nature in Systematic Reviews
- Vol. 15 (1)
Direct-acting antivirals for chronic hepatitis C infection: a protocol for a systematic review of observational studies
Chronic hepatitis C virus infection presents a substantial global health burden, frequently resulting in severe liver conditions. Hepatitis C virus (HCV) t
- 31 January 2026
- Published by Springer Nature in Systematic Reviews
- Vol. 15 (1)
Open AccessDirect-acting antivirals for chronic hepatitis C infection: a protocol for a systematic review of observational studies
Chronic hepatitis C virus infection presents a substantial global health burden, frequently resulting in severe liver conditions. Hepatitis C virus (HCV) t
- Open Access
- 1 January 2026
- Published by Wiley in Cardiovascular Therapeutics
- Vol. 2026 (1) , 9434123
Comparative Performance of Calcium‐Modification Strategies for Coronary Lesions: A Network Meta‐Analysis of Randomized Trials
Introduction and Objectives: Calcified coronary lesions are associated with an increased risk of percutaneous coronary intervention (PCI) failure. Despite the availability of several calcium‐modification strategies and randomized trials evaluating their efficacy, comparative investigations remain scanty. The aim of the present analysis is to assess the comparative performance of calcium‐modification strategies in patients undergoing PCI of calcified coronary lesions. Methods: We conducted a systematic search for randomized trials evaluating calcium‐modification strategies in patients undergoing PCI. Random‐effects network meta‐analyses were performed. The primary outcome was minimal stent area (MSA). Secondary outcomes included all‐cause death and stent thrombosis. Results: Twenty‐two trials enrolling 4855 patients were included. Compared to calcium modification with noncompliant balloons, the use of cutting/scoring balloon (mean difference: 0.81 mm 2 , 95% confidence interval: [0.36, 1.27]; p = 0.001), super high‐pressure balloon (SHPB, 0.95 mm 2 [0.18, 1.72]; p = 0.016), intravascular lithotripsy (IVL, 0.87 mm 2 [0.40, 1.34]; p < 0.001), rotational atherectomy (RA, 0.90 mm 2 [0.30, 1.50]; p = 0.003), and RA plus cutting balloon (1.24 mm 2 [0.46, 2.02]; p = 0.002) led to larger MSA. According to a network ranking analysis, RA, SHPB, and IVL were possibly the best treatment options in terms of MSA. There were no significant differences in clinical outcomes between calcium‐modification strategies. Conclusions: Compared with standard noncompliant balloons, RA and balloon‐based strategies improved the mechanical performance of PCI in calcified coronary lesions. However, this did not result in better clinical outcomes.
- 1 January 2026
- Published by Wiley in Cardiovascular Therapeutics
- Vol. 2026 (1) , 9434123
Open AccessComparative Performance of Calcium‐Modification Strategies for Coronary Lesions: A Network Meta‐Analysis of Randomized Trials
Introduction and Objectives: Calcified coronary lesions are associated with an increased risk of percutaneous coronary intervention (PCI) failure. Despite the availability of several calcium‐modification strategies and randomized trials evaluating their efficacy, comparative investigations remain scanty. The aim of the present analysis is to assess the comparative performance of calcium‐modification strategies in patients undergoing PCI of calcified coronary lesions. Methods: We conducted a systematic search for randomized trials evaluating calcium‐modification strategies in patients undergoing PCI. Random‐effects network meta‐analyses were performed. The primary outcome was minimal stent area (MSA). Secondary outcomes included all‐cause death and stent thrombosis. Results: Twenty‐two trials enrolling 4855 patients were included. Compared to calcium modification with noncompliant balloons, the use of cutting/scoring balloon (mean difference: 0.81 mm 2 , 95% confidence interval: [0.36, 1.27]; p = 0.001), super high‐pressure balloon (SHPB, 0.95 mm 2 [0.18, 1.72]; p = 0.016), intravascular lithotripsy (IVL, 0.87 mm 2 [0.40, 1.34]; p < 0.001), rotational atherectomy (RA, 0.90 mm 2 [0.30, 1.50]; p = 0.003), and RA plus cutting balloon (1.24 mm 2 [0.46, 2.02]; p = 0.002) led to larger MSA. According to a network ranking analysis, RA, SHPB, and IVL were possibly the best treatment options in terms of MSA. There were no significant differences in clinical outcomes between calcium‐modification strategies. Conclusions: Compared with standard noncompliant balloons, RA and balloon‐based strategies improved the mechanical performance of PCI in calcified coronary lesions. However, this did not result in better clinical outcomes.
- Open Access
- 15 December 2025
- Published by Elsevier in JACC: Cardiovascular Interventions
Balloon Lithotripsy Added to Conventional Preparation Before Stent Implantation in Severely Calcified Coronary Lesions
- 15 December 2025
- Published by Elsevier in JACC: Cardiovascular Interventions
Open AccessBalloon Lithotripsy Added to Conventional Preparation Before Stent Implantation in Severely Calcified Coronary Lesions
- Open Access
- 19 November 2025
- Published by Radcliffe Medical Media Ltd in Interventional Cardiology: Reviews, Research, Resources
- Vol. 20
Percutaneous Coronary Interventions for Calcified Lesions: A Systematic Review with Meta-analyses of Randomised Trials
Background: Coronary arterial calcification impedes safe and predictable percutaneous coronary intervention (PCI), and guidelines recommend calcium modification. Several interventional techniques exist, but the most optimal technique remains unclear. The aim of this study was therefore to assess the effects of PCI strategies for calcified lesions on all-cause mortality and serious adverse events. Methods: A systematic review with meta-analysis and trial sequential analysis of randomised trials was conducted to compare any lesion preparation or stenting technique in patients undergoing PCI for moderately or severely calcified coronary lesions according to a published protocol. CENTRAL, MEDLINE, Embase and other sources were searched up to 8 May 2025. Results: Out of 7,172 identified records, 31 eligible trials (8,453 participants) assessed 16 lesion preparation techniques (4,392 participants) and five stenting/scaffold techniques (4,061 participants). Lesion preparation comparisons were generally underpowered, and all showed no effect on all-cause mortality or serious adverse events. For stenting strategies, meta-analysis and trial sequential analysis showed that an effect of stent polymer coating (bioresorbable, permanent or polymer-free) on all-cause mortality or serious adverse events could be rejected. Conclusion: For patients undergoing PCI for moderately or severely calcified coronary lesions, there appears to be no significant differences between lesion preparation techniques regarding all-cause mortality or serious adverse events. Current evidence is underpowered and of low certainty, highlighting the clinical equipoise between available calcium modification techniques and the necessity for adequately powered randomised trials.
- 19 November 2025
- Published by Radcliffe Medical Media Ltd in Interventional Cardiology: Reviews, Research, Resources
- Vol. 20
Open AccessPercutaneous Coronary Interventions for Calcified Lesions: A Systematic Review with Meta-analyses of Randomised Trials
Background: Coronary arterial calcification impedes safe and predictable percutaneous coronary intervention (PCI), and guidelines recommend calcium modification. Several interventional techniques exist, but the most optimal technique remains unclear. The aim of this study was therefore to assess the effects of PCI strategies for calcified lesions on all-cause mortality and serious adverse events. Methods: A systematic review with meta-analysis and trial sequential analysis of randomised trials was conducted to compare any lesion preparation or stenting technique in patients undergoing PCI for moderately or severely calcified coronary lesions according to a published protocol. CENTRAL, MEDLINE, Embase and other sources were searched up to 8 May 2025. Results: Out of 7,172 identified records, 31 eligible trials (8,453 participants) assessed 16 lesion preparation techniques (4,392 participants) and five stenting/scaffold techniques (4,061 participants). Lesion preparation comparisons were generally underpowered, and all showed no effect on all-cause mortality or serious adverse events. For stenting strategies, meta-analysis and trial sequential analysis showed that an effect of stent polymer coating (bioresorbable, permanent or polymer-free) on all-cause mortality or serious adverse events could be rejected. Conclusion: For patients undergoing PCI for moderately or severely calcified coronary lesions, there appears to be no significant differences between lesion preparation techniques regarding all-cause mortality or serious adverse events. Current evidence is underpowered and of low certainty, highlighting the clinical equipoise between available calcium modification techniques and the necessity for adequately powered randomised trials.
- Open Access
Direct-acting antivirals for chronic hepatitis C infection: a protocol for a systematic review of observational studies
Background: Chronic hepatitis C virus infection presents a substantial global health burden, frequently resulting in severe liver conditions. Hepatitis C virus (HCV) therapy requires complex decision-making. Direct-acting antivirals (DAAs) offer a potential solution by targeting viral proteins to inhibit replication. Understanding DAAs real-world effectiveness and how they impact long-term outcomes beyond clinical trials is essential. We aim to comprehensively evaluate the benefits and harms of DAAs in individuals with chronic HCV infection, reported in observational studies. Methods: We will consider for inclusion prospective and retrospective observational studies with quasirandomised, cohort, case-control, controlled before-and-after, and cross-sectional designs. Our experimental interventions will be any class of DAAs available on the market or in development. DAAs could have been administered alone, in combination, or with other medical co-interventions. Our control interventions will be untreated chronic HCV conditions, with or without placebo. Participants will be adults, regardless of demographics, treatment history, or healthcare setting. Our primary outcomes will be participants experiencing hepatitis C-related morbidity or all-cause mortality, serious adverse events, and health-related quality of life. Secondary outcomes will include all-cause mortality, cirrhosis, variceal bleeding, hepato-renal syndrome, hepatocellular carcinoma, hepatic encephalopathy, non-serious adverse events, liver transplantation, lack of sustained virological response, histological improvement, and decreases in alanine aminotransferase and aspartate aminotransferase levels. We will apply search strategies to search MEDLINE, Embase, Web of Science, grey literature, and trial registers. We will use Covidence ® to screen the result, including citations. Individual double-data extraction will include study details and outcomes, with independent review authors resolving discrepancies. We will assess bias using the ROBINS-I tool. Meta-analyses will employ random-effects models for both dichotomous and continuous outcomes, assessing heterogeneity. Subgroup and sensitivity analyses will explore effect modifications and address missing data. Trial Sequential Analysis will control type I and type II errors. We will evaluate publication bias using funnel plots and Egger’s regression test and assess certainty of evidence using GRADE. Discussion: The findings will inform clinical decisions and benefit those affected by HCV, healthcare professionals, and policymakers. Systematic review registration: PROSPERO: CRD42023494844
Open AccessDirect-acting antivirals for chronic hepatitis C infection: a protocol for a systematic review of observational studies
Background: Chronic hepatitis C virus infection presents a substantial global health burden, frequently resulting in severe liver conditions. Hepatitis C virus (HCV) therapy requires complex decision-making. Direct-acting antivirals (DAAs) offer a potential solution by targeting viral proteins to inhibit replication. Understanding DAAs real-world effectiveness and how they impact long-term outcomes beyond clinical trials is essential. We aim to comprehensively evaluate the benefits and harms of DAAs in individuals with chronic HCV infection, reported in observational studies. Methods: We will consider for inclusion prospective and retrospective observational studies with quasirandomised, cohort, case-control, controlled before-and-after, and cross-sectional designs. Our experimental interventions will be any class of DAAs available on the market or in development. DAAs could have been administered alone, in combination, or with other medical co-interventions. Our control interventions will be untreated chronic HCV conditions, with or without placebo. Participants will be adults, regardless of demographics, treatment history, or healthcare setting. Our primary outcomes will be participants experiencing hepatitis C-related morbidity or all-cause mortality, serious adverse events, and health-related quality of life. Secondary outcomes will include all-cause mortality, cirrhosis, variceal bleeding, hepato-renal syndrome, hepatocellular carcinoma, hepatic encephalopathy, non-serious adverse events, liver transplantation, lack of sustained virological response, histological improvement, and decreases in alanine aminotransferase and aspartate aminotransferase levels. We will apply search strategies to search MEDLINE, Embase, Web of Science, grey literature, and trial registers. We will use Covidence ® to screen the result, including citations. Individual double-data extraction will include study details and outcomes, with independent review authors resolving discrepancies. We will assess bias using the ROBINS-I tool. Meta-analyses will employ random-effects models for both dichotomous and continuous outcomes, assessing heterogeneity. Subgroup and sensitivity analyses will explore effect modifications and address missing data. Trial Sequential Analysis will control type I and type II errors. We will evaluate publication bias using funnel plots and Egger’s regression test and assess certainty of evidence using GRADE. Discussion: The findings will inform clinical decisions and benefit those affected by HCV, healthcare professionals, and policymakers. Systematic review registration: PROSPERO: CRD42023494844
- Open Access
Drug interventions for prevention of COVID-19 progression to severe disease in outpatients: a systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Objectives: To assess the effects of interventions authorised by the European Medicines Agency (EMA) or the US Food and Drug Administration (FDA) for prevention of COVID-19 progression to severe disease in outpatients. Setting: Outpatient treatment. Participants: Participants with a diagnosis of COVID-19 and the associated SARS-CoV-2 virus irrespective of age, sex and comorbidities. Interventions: Drug interventions authorised by EMA or FDA. Primary outcome measures: Primary outcomes were all-cause mortality and serious adverse events. Results: We included 17 clinical trials randomising 16 257 participants to 8 different interventions authorised by EMA or FDA. 15/17 of the included trials (88.2%) were assessed at high risk of bias. Only molnupiravir and ritonavir-boosted nirmatrelvir seemed to improve both our primary outcomes. Meta-analyses showed that molnupiravir reduced the risk of death (relative risk (RR) 0.11, 95% CI 0.02 to 0.64; p=0.0145, 2 trials; very low certainty of evidence) and serious adverse events (RR 0.63, 95% CI 0.47 to 0.84; p=0.0018, 5 trials; very low certainty of evidence). Fisher’s exact test showed that ritonavir-boosted nirmatrelvir reduced the risk of death (p=0.0002, 1 trial; very low certainty of evidence) and serious adverse events (p < 0.0001, 1 trial; very low certainty of evidence) in 1 trial including 2246 patients, while another trial including 1140 patients reported 0 deaths in both groups. Conclusions: The certainty of the evidence was very low, but, from the results of this study, molnupiravir showed the most consistent benefit and ranked highest among the approved interventions for prevention of COVID-19 progression to severe disease in outpatients. The lack of certain evidence should be considered when treating patients with COVID-19 for prevention of disease progression. PROSPERO registration number: CRD42020178787.
Open AccessDrug interventions for prevention of COVID-19 progression to severe disease in outpatients: a systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Objectives: To assess the effects of interventions authorised by the European Medicines Agency (EMA) or the US Food and Drug Administration (FDA) for prevention of COVID-19 progression to severe disease in outpatients. Setting: Outpatient treatment. Participants: Participants with a diagnosis of COVID-19 and the associated SARS-CoV-2 virus irrespective of age, sex and comorbidities. Interventions: Drug interventions authorised by EMA or FDA. Primary outcome measures: Primary outcomes were all-cause mortality and serious adverse events. Results: We included 17 clinical trials randomising 16 257 participants to 8 different interventions authorised by EMA or FDA. 15/17 of the included trials (88.2%) were assessed at high risk of bias. Only molnupiravir and ritonavir-boosted nirmatrelvir seemed to improve both our primary outcomes. Meta-analyses showed that molnupiravir reduced the risk of death (relative risk (RR) 0.11, 95% CI 0.02 to 0.64; p=0.0145, 2 trials; very low certainty of evidence) and serious adverse events (RR 0.63, 95% CI 0.47 to 0.84; p=0.0018, 5 trials; very low certainty of evidence). Fisher’s exact test showed that ritonavir-boosted nirmatrelvir reduced the risk of death (p=0.0002, 1 trial; very low certainty of evidence) and serious adverse events (p < 0.0001, 1 trial; very low certainty of evidence) in 1 trial including 2246 patients, while another trial including 1140 patients reported 0 deaths in both groups. Conclusions: The certainty of the evidence was very low, but, from the results of this study, molnupiravir showed the most consistent benefit and ranked highest among the approved interventions for prevention of COVID-19 progression to severe disease in outpatients. The lack of certain evidence should be considered when treating patients with COVID-19 for prevention of disease progression. PROSPERO registration number: CRD42020178787.
- Open Access
Percutaneous coronary intervention in calcified stenoses: a protocol for a systematic review with meta-analysis, trial sequential analysis and network meta-analysis
Introduction Severely calcified coronary stenoses are difficult to treat with percutaneous coronary interventions. The presence of severe calcifications complicates lesion preparation, advancement of stents and achievement of full stent expansion. Intervention in these lesions is associated with an increased risk of complications and procedural failure compared with treatment of less calcified lesions. Due to the high burden of comorbidity, patients with severely calcified lesions are often excluded from interventional trials, and there is little evidence on how to treat these patients. Methods and analysis We will conduct a systematic review of randomised trials enrolling patients with calcified coronary artery disease undergoing percutaneous coronary intervention. We will investigate any percutaneous treatment option including any lesion preparation, stenting or postdilatation technique. We will search The Cochrane Central Register of Controlled Trials, Medical Literature Analysis and Retrieval System Online, Latin American and Caribbean Health Sciences Literature, Science Citation Index Expanded, and Excerpta Medica database for studies from inception to 31 October 2022. The coprimary outcome is all-cause mortality and serious adverse events. If appropriate, we will conduct meta-analysis, trial sequential analysis and network meta-analysis. Ethics and dissemination No ethics approval is required for this study. The results will be published in a peer-reviewed journal in this field. PROSPERO registration number CRD42021226034.
Open AccessPercutaneous coronary intervention in calcified stenoses: a protocol for a systematic review with meta-analysis, trial sequential analysis and network meta-analysis
Introduction Severely calcified coronary stenoses are difficult to treat with percutaneous coronary interventions. The presence of severe calcifications complicates lesion preparation, advancement of stents and achievement of full stent expansion. Intervention in these lesions is associated with an increased risk of complications and procedural failure compared with treatment of less calcified lesions. Due to the high burden of comorbidity, patients with severely calcified lesions are often excluded from interventional trials, and there is little evidence on how to treat these patients. Methods and analysis We will conduct a systematic review of randomised trials enrolling patients with calcified coronary artery disease undergoing percutaneous coronary intervention. We will investigate any percutaneous treatment option including any lesion preparation, stenting or postdilatation technique. We will search The Cochrane Central Register of Controlled Trials, Medical Literature Analysis and Retrieval System Online, Latin American and Caribbean Health Sciences Literature, Science Citation Index Expanded, and Excerpta Medica database for studies from inception to 31 October 2022. The coprimary outcome is all-cause mortality and serious adverse events. If appropriate, we will conduct meta-analysis, trial sequential analysis and network meta-analysis. Ethics and dissemination No ethics approval is required for this study. The results will be published in a peer-reviewed journal in this field. PROSPERO registration number CRD42021226034.
- 9 March 2020
- Published by Springer Nature in Hernia
- Vol. 24 (4) , 695-705
Long-term patient-reported outcomes and quality of the evidence in ventral hernia mesh repair: a systematic review
Purpose Patient-reported outcome measures (PROMs) have been increasingly accepted to evaluate the quality of surgery. The impact of a hernia on PROMs and the indication for elective ventral hernia mesh repair are poorly researched. The primary objective in this systematic review was to provide evidence for PROM changes at least 3 months after elective ventral hernia mesh repair. Secondarily, a critical appraisal of the study quality was undertaken. Methods Ovid MEDLINE, PubMed, Ovid Embase, and CENTRAL were searched (year 2000–May 12, 2019) for studies reporting any of 21 predefined PROMs pre- and ≥ 3 months postoperatively following adult ventral hernia mesh repair. A pre-study defined analysis method was used to assess pre- vs. postoperative PROM changes. Quality assessment was guided by criteria formulated by the National Institutes of Health. Results The search yielded 11,438 potentially eligible studies of which 24 met the inclusion criteria. Most studies were of poor or moderate quality and one study was of high quality. There was no evidence for a clinically relevant postoperative improvement in any PROM following umbilical hernia repair or medium-sized incisional hernia repair. A clinically relevant postoperative improvement of pain, physical impairment, and social involvement was seen in patients with a large-sized incisional hernia repair and stoma-related complaints in patients with a medium-sized parastomal hernia repair. Conclusion This analysis suggested that a minor subset of PROMs improved in patients undergoing large-sized incisional and medium-sized parastomal hernia repair. High-quality studies are imperative in this extremely often conducted surgical procedure. Trial registration The review was registered at PROSPERO (CRD42018096671, https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=96671).
- 9 March 2020
- Published by Springer Nature in Hernia
- Vol. 24 (4) , 695-705
Long-term patient-reported outcomes and quality of the evidence in ventral hernia mesh repair: a systematic review
Purpose Patient-reported outcome measures (PROMs) have been increasingly accepted to evaluate the quality of surgery. The impact of a hernia on PROMs and the indication for elective ventral hernia mesh repair are poorly researched. The primary objective in this systematic review was to provide evidence for PROM changes at least 3 months after elective ventral hernia mesh repair. Secondarily, a critical appraisal of the study quality was undertaken. Methods Ovid MEDLINE, PubMed, Ovid Embase, and CENTRAL were searched (year 2000–May 12, 2019) for studies reporting any of 21 predefined PROMs pre- and ≥ 3 months postoperatively following adult ventral hernia mesh repair. A pre-study defined analysis method was used to assess pre- vs. postoperative PROM changes. Quality assessment was guided by criteria formulated by the National Institutes of Health. Results The search yielded 11,438 potentially eligible studies of which 24 met the inclusion criteria. Most studies were of poor or moderate quality and one study was of high quality. There was no evidence for a clinically relevant postoperative improvement in any PROM following umbilical hernia repair or medium-sized incisional hernia repair. A clinically relevant postoperative improvement of pain, physical impairment, and social involvement was seen in patients with a large-sized incisional hernia repair and stoma-related complaints in patients with a medium-sized parastomal hernia repair. Conclusion This analysis suggested that a minor subset of PROMs improved in patients undergoing large-sized incisional and medium-sized parastomal hernia repair. High-quality studies are imperative in this extremely often conducted surgical procedure. Trial registration The review was registered at PROSPERO (CRD42018096671, https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=96671).